298 related articles for article (PubMed ID: 26575690)
41. Therapeutic approaches to treat human spliceosomal diseases.
DeNicola AB; Tang Y
Curr Opin Biotechnol; 2019 Dec; 60():72-81. PubMed ID: 30772756
[TBL] [Abstract][Full Text] [Related]
42. Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors.
Soret J; Bakkour N; Maire S; Durand S; Zekri L; Gabut M; Fic W; Divita G; Rivalle C; Dauzonne D; Nguyen CH; Jeanteur P; Tazi J
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8764-9. PubMed ID: 15939885
[TBL] [Abstract][Full Text] [Related]
43. Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling.
Pollyea DA; Harris C; Rabe JL; Hedin BR; De Arras L; Katz S; Wheeler E; Bejar R; Walter MJ; Jordan CT; Pietras EM; Alper S
Haematologica; 2019 Sep; 104(9):e388-e392. PubMed ID: 30846499
[No Abstract] [Full Text] [Related]
44. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer.
Bowling EA; Wang JH; Gong F; Wu W; Neill NJ; Kim IS; Tyagi S; Orellana M; Kurley SJ; Dominguez-Vidaña R; Chung HC; Hsu TY; Dubrulle J; Saltzman AB; Li H; Meena JK; Canlas GM; Chamakuri S; Singh S; Simon LM; Olson CM; Dobrolecki LE; Lewis MT; Zhang B; Golding I; Rosen JM; Young DW; Malovannaya A; Stossi F; Miles G; Ellis MJ; Yu L; Buonamici S; Lin CY; Karlin KL; Zhang XH; Westbrook TF
Cell; 2021 Jan; 184(2):384-403.e21. PubMed ID: 33450205
[TBL] [Abstract][Full Text] [Related]
45. Splicing-factor alterations in cancers.
Anczuków O; Krainer AR
RNA; 2016 Sep; 22(9):1285-301. PubMed ID: 27530828
[TBL] [Abstract][Full Text] [Related]
46. Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.
Damm F; Nguyen-Khac F; Fontenay M; Bernard OA
Leukemia; 2012 Sep; 26(9):2027-31. PubMed ID: 22484420
[TBL] [Abstract][Full Text] [Related]
47. Charting the "Splice" Routes to MDS.
Obeng EA; Ebert BL
Cancer Cell; 2015 May; 27(5):607-9. PubMed ID: 25965565
[TBL] [Abstract][Full Text] [Related]
48. Dysregulation of splicing variants and spliceosome components in breast cancer.
Gahete MD; Herman-Sanchez N; Fuentes-Fayos AC; Lopez-Canovas JL; Luque RM
Endocr Relat Cancer; 2022 Sep; 29(9):R123-R142. PubMed ID: 35728261
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic targeting of RNA splicing in myelodysplasia.
Kim YJ; Abdel-Wahab O
Semin Hematol; 2017 Jul; 54(3):167-173. PubMed ID: 28958291
[TBL] [Abstract][Full Text] [Related]
50. Spliceosomal RNA infrastructure: the network of splicing components and their regulation by miRNAs.
Collins LJ
Adv Exp Med Biol; 2011; 722():86-102. PubMed ID: 21915784
[TBL] [Abstract][Full Text] [Related]
51. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome.
Colla S; Ong DS; Ogoti Y; Marchesini M; Mistry NA; Clise-Dwyer K; Ang SA; Storti P; Viale A; Giuliani N; Ruisaard K; Ganan Gomez I; Bristow CA; Estecio M; Weksberg DC; Ho YW; Hu B; Genovese G; Pettazzoni P; Multani AS; Jiang S; Hua S; Ryan MC; Carugo A; Nezi L; Wei Y; Yang H; D'Anca M; Zhang L; Gaddis S; Gong T; Horner JW; Heffernan TP; Jones P; Cooper LJ; Liang H; Kantarjian H; Wang YA; Chin L; Bueso-Ramos C; Garcia-Manero G; DePinho RA
Cancer Cell; 2015 May; 27(5):644-57. PubMed ID: 25965571
[TBL] [Abstract][Full Text] [Related]
52. Functional splicing network reveals extensive regulatory potential of the core spliceosomal machinery.
Papasaikas P; Tejedor JR; Vigevani L; Valcárcel J
Mol Cell; 2015 Jan; 57(1):7-22. PubMed ID: 25482510
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of a spliceosome turnover pathway suppresses splicing defects.
Pandit S; Lynn B; Rymond BC
Proc Natl Acad Sci U S A; 2006 Sep; 103(37):13700-5. PubMed ID: 16945917
[TBL] [Abstract][Full Text] [Related]
54. Human papillomavirus regulation of SR proteins.
McFarlane M; Graham SV
Biochem Soc Trans; 2010 Aug; 38(4):1116-21. PubMed ID: 20659014
[TBL] [Abstract][Full Text] [Related]
55. Alternative splicing and cancer metastasis: prognostic and therapeutic applications.
Marzese DM; Manughian-Peter AO; Orozco JIJ; Hoon DSB
Clin Exp Metastasis; 2018 Aug; 35(5-6):393-402. PubMed ID: 29845349
[TBL] [Abstract][Full Text] [Related]
56. Targeting splicing factors for cancer therapy.
Bashari A; Siegfried Z; Karni R
RNA; 2023 Apr; 29(4):506-515. PubMed ID: 36697261
[TBL] [Abstract][Full Text] [Related]
57. In Brief: (mis)splicing in disease.
Pedrotti S; Cooper TA
J Pathol; 2014 May; 233(1):1-3. PubMed ID: 24615176
[TBL] [Abstract][Full Text] [Related]
58. The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia.
Federmann B; Abele M; Rosero Cuesta DS; Vogel W; Boiocchi L; Kanz L; Quintanilla-Martinez L; Orazi A; Bonzheim I; Fend F
Hum Pathol; 2014 Dec; 45(12):2471-9. PubMed ID: 25305095
[TBL] [Abstract][Full Text] [Related]
59. Improving the outlook for myelodysplastic syndrome.
Brower V
J Natl Cancer Inst; 2012 Aug; 104(16):1204-6. PubMed ID: 22899627
[No Abstract] [Full Text] [Related]
60. Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.
Shirai CL; Ley JN; White BS; Kim S; Tibbitts J; Shao J; Ndonwi M; Wadugu B; Duncavage EJ; Okeyo-Owuor T; Liu T; Griffith M; McGrath S; Magrini V; Fulton RS; Fronick C; O'Laughlin M; Graubert TA; Walter MJ
Cancer Cell; 2015 May; 27(5):631-43. PubMed ID: 25965570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
